| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 11, 2006
Accepted on December 6, 2006
Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60637, the Department of Physiology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201
* To whom correspondence should be addressed. E-mail: dskafar{at}med.wayne.edu or skoide{at}uchicago.edu.
The estrogen receptor alpha (ER
) is a biologically and clinically important ligand-modulated transcription factor. The F domain of the ER
modulates its functions in a ligand-, promoter-, and cell-specific manner. To identify the region(s) responsible for these functions, we characterized the effects of serial truncations within the F domain. We found that truncating the last 16 residues of the F-domain altered the activity of the hER
on an ERE-driven promoter in response to estradiol (E2) or 4-hydroxytamoxifen (4-OHT), its sensitivity to overexpression of the coactivator SRC-1 in mammalian cells, and its interaction with a receptor-interacting domain (RID) of the coactivator SRC-1 or engineered proteins ("monobodies") that specifically bind to ER
/ligand complexes in a yeast two-hybrid system. Most importantly, the ability of the ER to induce pS2 was reduced in MDA-MB-231 cells stably expressing this truncated ER vs the wt ER. The region includes a distinctive segment (residues 579-584; LQKYYIT) having a high content of bulky and/or hydrophobic amino acids that was previously predicted to adopt a
-strand-like structure. As previously reported, removal of the entire F domain was necessary to eliminate the agonist activity of 4-OHT. In addition, mutation of the vicinal glycine residues between the LBD and F domains specifically reduced the 4-OHT-dependent interactions of the hER
LBD and F domains with monobodies. These results show that regions within the F domain of the hER
selectively modulate its activity and its interactions with other proteins.
NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
D. J Kojetin, T. P Burris, E. V Jensen, and S. A Khan Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor Endocr. Relat. Cancer, December 1, 2008; 15(4): 851 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Sonoda, L. Martinez, P. Webb, M. S. Skaf, and I. Polikarpov Ligand Dissociation from Estrogen Receptor Is Mediated by Receptor Dimerization: Evidence from Molecular Dynamics Simulations Mol. Endocrinol., July 1, 2008; 22(7): 1565 - 1578. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |